You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm saw strong increases in international HIV sales of its OraQuick HIV Self-Test product in the quarter.
China remains a key strategic market for Roche, and it said that it has multiple assays for 2019-nCoV coronavirus for research-use only.
Within diagnostics, the firm posted molecular diagnostics revenues of $178.5 million, up 9 percent from $164.3 million in fiscal Q1 2019.
The clearance covers tests made by the firm's joint venture for manufacturing, CoSara Diagnostics, in its facility in Ranoli, India.
The firm is also targeting a new market for oral fluid-based tests for drugs of abuse, projecting future growth due to new federal regulations.
OraSure will purchase Houston-based Diversigen, a microbiome and metagenomics consulting, sequencing, and data analysis service provider.
It is the first time that the agency has authorized for marketing a next-generation sequencing test for HIV-1 resistance, the FDA noted.
Two new grants are helping the company develop its SHERLOCK and INSPECTR technologies as the basis for creating innovative diagnostics.
The company said that the decline in revenues reflected lower industry-wide reimbursement rates under PAMA.
Investigators at the Foundation for Research and Technology - Hellas, a Greek research institute, are coordinating the effort.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.